A drawing of a person with a healthy arm muscle is shown on the left. An arrow points to a drawing of a person with a dystrophied muscle in a circle on the right.

Dystrophied muscle

Shannon Herring

Infographic: CRISPR editing for treating Duchenne muscular dystrophy

Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.
Natalya Ortolano, PhD Headshot
| 1 min read

Duchenne muscular dystrophy is a rare genetic disorder that causes muscles to slowly break down over time, leading to symptoms such as difficulty walking. Dysfunction of the muscle stabilizing protein dystrophin is the primary cause of the disease. The biotech company MyoGeneBio uses CRISPR gene editing to restore partial function of dystrophin to minimize symptoms and slow the progression of disease.

Download the infographic: CRISPR editing for treating Duchenne muscular dystrophy

By Natalya Ortolano, PhD
illustrated by Shannon herring

About the Author

  • Natalya Ortolano, PhD Headshot

    Natalya received her PhD in from Vanderbilt University in 2021; she joined the DDN team the same week she defended her thesis. Her work has been featured at STAT News, Vanderbilt Magazine, and Scientific American. As an assistant editor, she writes and edits online and print stories on topics ranging from cows to psychedelics. Outside of work you can probably find her at a concert in her hometown Nashville, TN.

Related Topics

Published In

October 2021 Issue, Drug Discovery News
Volume 17 - Issue 10 | October 2021

October 2021

October 2021 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue